295 related articles for article (PubMed ID: 11589914)
1. Acetylcholinesterase in Alzheimer's disease.
Talesa VN
Mech Ageing Dev; 2001 Nov; 122(16):1961-9. PubMed ID: 11589914
[TBL] [Abstract][Full Text] [Related]
2. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.
Unni L; Vicari S; Moriearty P; Schaefer F; Becker R
Methods Find Exp Clin Pharmacol; 2000; 22(1):57-61. PubMed ID: 10791297
[TBL] [Abstract][Full Text] [Related]
3. Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor.
Mimori Y; Nakamura S; Yukawa M
Behav Brain Res; 1997 Feb; 83(1-2):25-30. PubMed ID: 9062656
[TBL] [Abstract][Full Text] [Related]
4. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease.
Rees TM; Brimijoin S
Drugs Today (Barc); 2003 Jan; 39(1):75-83. PubMed ID: 12669110
[TBL] [Abstract][Full Text] [Related]
5. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease.
Sáez-Valero J; Sberna G; McLean CA; Small DH
J Neurochem; 1999 Apr; 72(4):1600-8. PubMed ID: 10098867
[TBL] [Abstract][Full Text] [Related]
6. Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer's cerebrospinal fluid.
García-Ayllón MS; Silveyra MX; Sáez-Valero J
Chem Biol Interact; 2008 Sep; 175(1-3):209-15. PubMed ID: 18554581
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
Darreh-Shori T; Kadir A; Almkvist O; Grut M; Wall A; Blomquist G; Eriksson B; Långström B; Nordberg A
Neurobiol Aging; 2008 Feb; 29(2):168-84. PubMed ID: 17196712
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Darreh-Shori T; Hellström-Lindahl E; Flores-Flores C; Guan ZZ; Soreq H; Nordberg A
J Neurochem; 2004 Mar; 88(5):1102-13. PubMed ID: 15009666
[TBL] [Abstract][Full Text] [Related]
9. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
10. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
12. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Mushtaq G; Greig NH; Khan JA; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
[TBL] [Abstract][Full Text] [Related]
13. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B; Singh N
Bioorg Med Chem; 2012 Feb; 20(3):1175-80. PubMed ID: 22257528
[TBL] [Abstract][Full Text] [Related]
14. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
[TBL] [Abstract][Full Text] [Related]
15. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD.
del Monte-Millán M; García-Palomero E; Valenzuela R; Usán P; de Austria C; Muñoz-Ruiz P; Rubio L; Dorronsoro I; Martínez A; Medina M
J Mol Neurosci; 2006; 30(1-2):85-8. PubMed ID: 17192640
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
17. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms.
Arendt T; Brückner MK; Lange M; Bigl V
Neurochem Int; 1992 Oct; 21(3):381-96. PubMed ID: 1303164
[TBL] [Abstract][Full Text] [Related]
18. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
19. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.
Castro A; Martinez A
Curr Pharm Des; 2006; 12(33):4377-87. PubMed ID: 17105433
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of acetylcholinesterase activity closely associated with amyloid beta/A4 protein is not correlated with acetylcholinesterase-positive fiber density in amygdala of Alzheimer's disease.
Nakamura S; Takemura M; Suenaga T; Akiguchi I; Kimura J; Yasuhara O; Kimura T; Kitaguchi N
Acta Neuropathol; 1992; 84(4):425-32. PubMed ID: 1441923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
